Vitamin D deficiency: Universal risk factor for multifactorial Diseases?

Current Drug Targets

Volumn 12, Issue 1, 2011, Pages 97-106

  de Borst, Martin H ^a   de Boer, Rudolf A ^a   Stolk, Ronald P ^a   Slaets, Joris P J ^a   Wolffenbuttel, Bruce H R ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Frailty; Multifactorial diseases; Universal risk factor; Vitamin D; Vitamin D receptor (VDR)

Indexed keywords

CALCIUM; GROWTH FACTOR; HORMONE; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; FRAIL ELDERLY; HUMAN; KIDNEY DYSFUNCTION; OSTEOMALACIA; RICKETS; RISK FACTOR; VITAMIN D DEFICIENCY; VITAMIN D RESPONSIVE ELEMENT;

ANIMALS; DIETARY SUPPLEMENTS; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; RECEPTORS, CALCITRIOL; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78650883769     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011793591590     Document Type: Article

References (133)

1. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary heart disease in men. Lancet 1987; 1: 821-821
2. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000; 160: 898-904.
3. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005; 95(Suppl 1): S144-50.
4. Stolk RP, Rosmalen JG, Postma DS, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008; 23: 67-74.
5. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
6. Whitfield GK, Remus LS, Jurutka PW, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001; 177: 145-159.
7. Mossetti G, Vuotto P, Rendina D, et al. Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis. J Intern Med 2003; 253: 194-200.
8. Wilke RA, Simpson RU, Mukesh BN, et al. Genetic variation in CYP27B1 is associated with congestive heart failure in patients with hypertension. Pharmacogenomics 2009; 10: 1789-1797.
9. Heist RS, Zhou W, Wang Z, et al. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 5596-5602.
10. Engelman CD, Fingerlin TE, Langefeld CD, et al. Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25- dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab 2008; 93: 3381-3388.
11. Peterson PA. Isolation and partial characterization of a human vitamin D-binding plasma protein. J Biol Chem 1971; 246: 7748-7754.
12. Schmidt-Gayk H, Grawunder C, Tschope W, et al. 25-hydroxy-vitamin-D in nephrotic syndrome. Lancet 1977; 2: 105-108.
13. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
14. Matsui I, Hamano T, Tomida K, et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009; 24: 2354-2361.
15. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photopro-duction of cholecalciferol in normal and uremic humans. J Nutr 1984; 114: 1313-1319.
16. Vieth R. The role of vitamin D in the prevention of osteoporosis. Ann Med 2005; 37: 278-285.
17. Doorenbos CR, van den BJ, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 2009; 5: 691-700.
18. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, wson-Hughes B. Estimation of optimal serum concentrations of 25- hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28.
19. Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004; 89-90: 611-614.
20. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-806.
21. [21] Carter GD. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin Chem 2009; 55: 1300-1302.
22. [22] Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D binding gene. Thorax 2010; [Epub ahead of print].
23. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the third national health and nutrition examination survey. Atherosclerosis 2009; 205: 255-2560.
24. Jean G, Charra B, Chazot C. Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 2008; 18: 395-399.
25. Wang AY, Lam CW, Sanderson JE, et al. Serum 25- hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 2008; 87: 1631-1638.
26. Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 2008; 65: 508-512.
27. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30: 113-125.
28. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176-1178.
29. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009; 100: 450-454.
30. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 1637-1642.
31. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-676.
32. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854.
33. Lambers Heerspink HJ, Agarwal R, Coyne DW, et al. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. Am J Nephrol 2009; 30: 280-286.
34. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-652.
35. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med 2008; 264: 599-609.
36. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25: 669-674.
37. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005; 97: 179-94.
38. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-696.
39. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006; 54: 991-1001.
40. Puts MT, Visser M, Twisk JW, Deeg DJ, Lips P. Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol (Oxf) 2005; 63: 403-411.
41. Semba RD, Houston DK, Ferrucci L, et al. Low serum 25- hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community-dwelling women. Nutr Res 2009; 29: 525-530.
42. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
43. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737.
44. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-5772.
45. Bischoff-Ferrari HA, wson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999-2006.
46. Cheskis B, Freedman LP. Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol Cell Biol 1994; 14: 3329-3338.
47. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-776.
48. Carlberg C, Bendik I, Wyss A, et al. Two nuclear signalling pathways for vitamin D. Nature 1993; 361: 657-660.
49. Eelen G, Gysemans C, Verlinden L, et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs. Curr Med Chem 2007; 14: 1893-1910.
50. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
51. Fedirko V, Bostick RM, Flanders WD, et al. Effects of vitamin D and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 2933-2941.
52. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001; 60: 2109-2117.
53. Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69: 1377-1384.
54. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-2309.
55. Kramer AB, Ricardo SD, Kelly DJ, Waanders F, van GH, Navis G. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. J Pathol 2005; 207: 483-492.
56. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009; 76: 32-43.
57. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009; 175: 473-478.
58. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; 92: 2814-2820.
59. Molostvov G, James S, Fletcher S, et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007; 293: F946-955.
60. Li X, Speer MY, Yang H, Bergen J, Giachelli CM. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010; 30: 321-326.
61. Doherty TM, Tang W, Dascalos S, et al. Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation 1997; 96: 1477-1481.
62. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-1760.
63. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
64. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
65. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
66. Kerr DN. Hypercalcemia and metastatic calcification. Cardiovasc Res 1997; 36: 293-297.
67. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
68. Yanagisawa J, Yanagi Y, Masuhiro Y, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283: 1317-1321.
69. Sanchez-Martinez R, Zambrano A, Castillo AI, Aranda A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol Cell Biol 2008; 28: 3817-329.
70. Tagami T, Lutz WH, Kumar R, Jameson JL. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 1998; 253: 358-363.
71. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
72. Kuipers I, van der HP, Navis G, et al. Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. Hypertension 2008; 51: 1442-148.
73. Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830.
74. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
75. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008; 19: 1741-1752.
76. Tse AK, Zhu GY, Wan CK, Shen XL, Yu ZL, Fong WF. 1alpha,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol Immunol 2010; 47: 1728-1738.
77. Szeto FL, Sun J, Kong J, et al. Involvement of the vitamin D receptor in the regulation of NF-kappaB activity in fibroblasts. J Steroid Biochem Mol Biol 2007; 103: 563-566.
78. Janjetovic Z, Zmijewski MA, Tuckey RC, et al. 20-Hydroxychole-calciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. PLoS One 2009; 4: e5988.
79. Zhang Z, Yuan W, Sun L, et al.1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193-201.
80. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 2007; 103: 558-62.
81. Misteli T. Beyond the sequence: cellular organization of genome function. Cell 2007; 128: 787-800.
82. Zilberman D, Gehring M, Tran RK, Ballinger T, Henikoff S. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet 2007; 39: 61-9.
83. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
84. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
85. Laukkanen MO, Mannermaa S, Hiltunen MO, et al. Local hypo-methylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol 1999; 19: 2171-8.
86. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methyla- tion of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43: 985-91.
87. Ying AK, Hassanain HH, Roos CM, et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res 2000; 46: 172-9.
88. de Borst MH, Benigni A, Remuzzi G. Primer: strategies for identifying genes involved in renal disease. Nat Clin Pract Nephrol 2008; 4: 265-76.
89. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 2007; 18: 58-65.
90. Lin RK, Hsieh YS, Lin P, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010; 120: 521-32.
91. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536-40.
92. Kim MS, Kondo T, Takada I, et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009; 461: 1007-12.
93. Novakovic B, Sibson M, Ng HK, et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 2009; 284: 14838-48.
94. Kim MS, Fujiki R, Kitagawa H, Kato S. 1alpha,25(OH)2D3- induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol 2007; 265-266: 168-73.
95. Kim MS, Kato S. Epigenetic modifications involved in the opposing regulation of CYP27B1 expression by the vitamin D receptor and parathyroid hormone. J Steroid Biochem Mol Biol 2010.
96. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. MicroRNA regulates human vitamin D receptor. Int J Cancer 2009; 125: 1328-33.
97. Cross HS, Bareis P, Hofer H, et al. 25-Hydroxyvitamin D(3)- 1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001; 66: 287-92.
98. Friedrich M, xt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrath J. Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J 2002; 34: 35-40.
99. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post- transcriptionally regulated by miR-125b. Mol Pharmacol 2009; 76: 702-9.
100. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736-41.
101. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 2006; 34: 543-54.
102. Matilainen M, Malinen M, Saavalainen K, Carlberg C. Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res 2005; 33: 5521-32.
103. Cardus A, Panizo S, Encinas M, et al. 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009; 204: 85-9.
104. McGaffin KR, Chrysogelos SA. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol 2005; 35: 117-33.
105. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68: 1500-10.
106. Wu Y, Craig TA, Lutz WH, Kumar R. Identification of 1 alpha,25- dihydroxyvitamin D3 response elements in the human transforming growth factor beta 2 gene. Biochemistry 1999; 38: 2654-60.
107. Pike JW, Zella LA, Meyer MB, Fretz JA, Kim S. Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in calcium homeostasis. J Bone Miner Res 2007; 22(Suppl 2): V16-9.
108. Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25- dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 2006; 26: 6469-86.
109. 2+ channel TRPV6 in the kidney. J Am Soc Nephrol 2003; 14: 2731-40.
110. Shen Q, Christakos S. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem 2005; 280: 40589-98.
111. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002; 277: 30337-50.
112. Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25- dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer 2008; 122: 2699-706.
113. Hakim I, Bar-Shavit Z. Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem 2003; 88: 986-98.
114. Seuter S, Vaisanen S, Radmark O, Carlberg C, Steinhilber D. Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. Biochim Biophys Acta 2007; 1771: 864-72.
115. Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol 2008; 76: 531-42.
116. Okamura M, Takano Y, Saito Y, Yao J, Kitamura M. Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. Nephrol Dial Transplant 2009; 24: 3006-12.
117. Maestro B, Davila N, Carranza MC, Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84: 223-30.
118. Wehmeier K, Beers A, Haas MJ, et al. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta 2005; 1737: 16-26.
119. Sanchez CP, He YZ. Bone growth during daily or intermittent calcitriol treatment during renal failure with advanced secondary hyperparathyroidism. Kidney Int 2007; 72: 582-91.
120. Schwartz GG, Eads D, Naczki C, Northrup S, Chen T, Koumenis C. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 2008; 7: 430-6.
121. Nickerson T, Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999; 160: 223-9.
122. Naja RP, Dardenne O, Arabian A, St AR. Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. Endocrinology 2009; 150: 4024-32.
123. Ormerod AK, Xing Z, Pedigo NG, Mishra A, Kaetzel DM. The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung. Exp Lung Res 2008; 34: 155-82.
124. Zella LA, Meyer MB, Nerenz RD, Pike JW. The enhanced hypercalcemic response to 20-epi-1,25-dihydroxyvitamin D3 results from a selective and prolonged induction of intestinal calcium- regulating genes. Endocrinology 2009; 150: 3448-56.
125. Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, Dutz JP. Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol 2009; 182: 6071-8.
126. Fudge NJ, Kovacs CS. Pregnancy up-regulates intestinal calcium absorption and skeletal mineralization independently of the vitamin D receptor. Endocrinology 2010; 151: 886-95.
127. Lee GS, Jung EM, Choi KC, Oh GT, Jeung EB. Compensatory induction of the TRPV6 channel in a calbindin-D9k knockout mouse: Its regulation by 1,25-hydroxyvitamin D3. J Cell Biochem 2009; 108: 1175-83.
128. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 2002; 143: 1625-36.
129. Han KH, Jung JY, Cha JH, Kim H, Madsen KM, Kim J. 1,25- Dihydroxyvitamin D3 stimulates osteopontin expression in rat kidney. Nephron Physiol 2003; 93: 76-86.
130. Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague--Dawley rats. Int J Vitam Nutr Res 1996; 66: 39-45.
131. Nasr LB, Monet JD, Lucas P, Bader CA. Vitamin D3 and glucose- 6-phosphate dehydrogenase in rat duodenal epithelial cells. Am J Physiol 1989; 257: G760-5.
132. Coffey MJ, Wilcoxen SE, Phare SM, Simpson RU, Gyetko MR, Peters-Golden M. Reduced 5-lipoxygenase metabolism of arachidonic acid in macrophages rrom 1,25-dihydroxyvitamin D3- deficient rats. Prostaglandins 1994; 48: 313-29.
133. Xiao H, Shi W, Liu S, et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt- signaling pathway. Am J Nephrol 2009; 30: 34-43.